Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

After starting therapy for psoriasis, Asempa usually has a follow-up visit at 3 to 4 months. Patient feedback at that point carries a lot of weight with respect to next steps.

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...